Merck Collaborates with Instituto Butantan to Develop Vaccines for Dengue
Merck Collaborates with Instituto Butantan to Develop Vaccines for Dengue
Shots:
- Instituto Butantan to receive $26M upfront, $75M milestones and royalties on sales from Merck. Merck to get clinical data and learnings (utilized for its TV003, dengue vaccine) from Instituto’s development programs to develop vaccines for dengue
- The focus of the agreement is to develop live attenuated tetravalent vaccines (LATV) against the dengue virus for patients suffering in Brazil
- TV003 is a LATV P-III candidate, assessing 17,000 healthy people aged 2 to 59 years in 15 cities, indicated to treat dengue infection
Click here to read full press release/ article | Ref: Merck | Image: Endpoint News